a) Moderna
b) Johnson & Johnson
c) Sanofi
d) Pfizer
American drug giant Pfizer and its German partner BioNTech confirmed on November 18, 2020 that they have concluded the phase 3 study of their COVID-19 vaccine candidate. Pfizer’s BNT162b2 COVID vaccine was found to be 95 percent effective after the last-stage trial.